by Michael Nevradakis, Ph.D.
Pfizer and Bristol Myers Squibb this month revived the “No Time to Wait” ad campaign urging people experiencing heart issues to visit their doctors. The two drugmakers developed and market Eliquis, the top-selling drug for the very heart conditions associated with people who received Pfizer’s COVID vaccine.
Two major pharmaceutical companies chose February, the month of love — or hearts — to launch an advertising campaign urging people experiencing heart issues for the first time to visit their doctors.
The campaign warns anyone experiencing palpitations and shortness of breath that they may be at increased risk of developing atrial fibrillation (AF), deep vein thrombosis (DVT), other types of blood clots and strokes — the same types of cardiovascular ailments found among people who have received COVID-19 vaccines.
The campaign urges viewers to seek early medical attention in order to reduce the risk of these serious complications.
“Early medical attention” could include prescription drugs — including Eliquis, developed and marketed by none other than Pfizer and BMS.
According to industry publication Fierce Pharma:
“The aim is to get patients back into their doctors’ offices — and of course, if needed, be diagnosed with any relevant condition that may require them to take a blood thinner, such as Eliquis.”
Eliquis, described as a “blockbuster blood thinner and atrial fibrillation (AF) drug,” is a major revenue generator for the Pfizer-BMS alliance, delivering more than $9 billion in annual revenue — far more than competing drugs such as Xarelto (produced by Bayer in conjunction with Johnson & Johnson), and Pradaxa, produced by Boehringer Ingelheim.
Pfizer and BMS relaunched the “No Time to Wait” campaign in conjunction with several advocacy organizations and medical societies, including World Thrombosis Day, which expressed support for the Pfizer-BMS initiative as a means of “educating” the public.